The immunomodulatory effects of statins in community-acquired pneumonia: A systematic review

Journal of Infection

Volumn 67, Issue 2, 2013, Pages 93-101

  Troeman, D P R ^a   Postma, D F ^a   Van Werkhoven, C H ^a   Oosterheert, J J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Community acquired infections; HMG CoA; Immunomodulation; Pneumonia; Review; Statins; Systematic

Indexed keywords

CYTOKINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

CLINICAL STUDY; COMMUNITY ACQUIRED PNEUMONIA; CYTOKINE RELEASE; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; HUMAN; IMMUNOMODULATION; INFECTION RISK; LEUKOCYTE FUNCTION; LUNG PROTECTION; MORTALITY; NEUTROPHIL; PROTECTION; PROTEIN EXPRESSION; RESPIRATORY TRACT PARAMETERS; REVIEW; RISK ASSESSMENT; RISK REDUCTION; STUDY DESIGN; SYSTEMATIC REVIEW;

ANTICHOLESTEREMIC AGENTS; COMMUNITY-ACQUIRED INFECTIONS; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSION; PNEUMONIA, BACTERIAL;

EID: 84879299799     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2013.04.015     Document Type: Review

References (57)

1. Fry A.M., Shay D.K., Holman R.C., Curns A.T., Anderson L.J. Trends in hospitalizations for pneumonia among persons aged 65 years or older in the United States, 1988-2002. J Am Med Assoc 2005 Dec 7, 294(21):2712-2719.
2. Oosterheert J.J., Bonten M.J., Hak E., Lammers J.W., Schneider M.M., Hoepelman I.M. The increase in pneumonia-related morbidity and mortality among adults in the Netherlands and possible explanations for it. Ned Tijdschr Geneeskd 2004 Sep 4, 148(36):1765-1769.
3. Welte T., Torres A., Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax 2012 Jan, 67(1):71-79.
4. Mandell L.A., Wunderink R.G., Anzueto A., Bartlett J.G., Campbell G.D., Dean N.C., et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007 Mar 1, 44(Suppl. 2):S27-S72.
5. Viasus D., Garcia-Vidal C., Gudiol F., Carratala J. Statins for community-acquired pneumonia: current state of the science. Eur J Clin Microbiol Infect Dis 2010 Feb, 29(2):143-152.
6. Meijvis S.C., van de Garde E.M., Rijkers G.T., Bos W.J. Treatment with anti-inflammatory drugs in community-acquired pneumonia. J Intern Med 2012 Jul, 272(1):25-35.
7. Fifth Joint Task Force of the European Society of Cardiology, European Association of Echocardiography, European Association of Percutaneous Cardiovascular Interventions, European Heart Rhythm Association, Heart Failure Association, European Association for Cardiovascular Prevention & Rehabilitation, et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012): the Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur J Prev Cardiol 2012 Aug, 19(4):585-667.
8. Blum A., Shamburek R. The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis. Atherosclerosis 2009 Apr, 203(2):325-330.
9. Terblanche M., Almog Y., Rosenson R.S., Smith T.S., Hackam D.G. Statins and sepsis: multiple modifications at multiple levels. Lancet Infect Dis 2007 May, 7(5):358-368.
10. Boyd A.R., Hinojosa C., Rodriguez P.J., Orihuela C.J. Impact of oral simvastatin therapy on acute lung injury in mice during pneumococcal pneumonia. BMC Microbiol 2012 May 15, 12(1):73.
11. Kothe H., Dalhoff K., Rupp J., Muller A., Kreuzer J., Maass M., et al. Hydroxymethylglutaryl coenzyme A reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with Chlamydia pneumoniae. Circulation 2000 Apr 18, 101(15):1760-1763.
12. Iwata A., Shirai R., Ishii H., Kushima H., Otani S., Hashinaga K., et al. Inhibitory effect of statins on inflammatory cytokine production from human bronchial epithelial cells. Clin Exp Immunol 2012 May, 168(2):234-240.
13. Chen W., Sammani S., Mitra S., Ma S.F., Garcia J.G., Jacobson J.R. Critical role for integrin-beta4 in the attenuation of murine acute lung injury by simvastatin. Am J Physiol Lung Cell Mol Physiol 2012 Aug 15, 303(4):L279-L285.
14. McDowell S.A., Ma Y., Kusano R., Akinbi H.T. Simvastatin is protective during Staphylococcus aureus pneumonia. Curr Pharm Biotechnol 2011 Sep, 12(9):1455-1462.
15. Lee C.S., Yi E.H., Lee J.K., Won C., Lee Y.J., Shin M.K., et al. Simvastatin suppresses RANTES-mediated neutrophilia in poly I: C-induced pneumonia. Eur Respir J 2013 May, 41(5):1147-1156.
16. Shyamsundar M., McKeown S.T., O'Kane C.M., Craig T.R., Brown V., Thickett D.R., et al. Simvastatin decreases lipopolysaccharide-induced pulmonary inflammation in healthy volunteers. Am J Respir Crit Care Med 2009 Jun 15, 179(12):1107-1114.
17. Yao H.W., Mao L.G., Zhu J.P. Protective effects of pravastatin in murine lipopolysaccharide-induced acute lung injury. Clin Exp Pharmacol Physiol 2006 Sep, 33(9):793-797.
18. Rosch J.W., Boyd A.R., Hinojosa E., Pestina T., Hu Y., Persons D.A., et al. Statins protect against fulminant pneumococcal infection and cytolysin toxicity in a mouse model of sickle cell disease. J Clin Invest 2010 Feb, 120(2):627-635.
19. Yeo C.D., Rhee C.K., Kim I.K., Kang H.H., Lee S.H., Lee S.Y., et al. Protective effect of pravastatin on lipopolysaccharide-induced acute lung injury during neutropenia recovery in mice. Exp Lung Res 2013 Mar, 39(2):99-106.
20. Xing X.Q., Duan S., Wu X.W., Gan Y., Zhao S.P., Chen P., et al. Atorvastatin reduces lipopolysaccharide-induced expression of C-reactive protein in human lung epithelial cells. Mol Med Rep 2011 Jul-Aug, 4(4):753-757.
21. Wu B.Q., Luo J.M., Wang Y.H., Shi Y.F., Liu H., Ba J.H., et al. Inhibitory effects of simvastatin on staphylococcus aureus lipoteichoic acid-induced inflammation in human alveolar macrophages. Clin Exp Med 2013 Mar 3, [Epub ahead of print].
22. Dobesh P.P., Swahn S.M., Peterson E.J., Olsen K.M. Statins in sepsis. J Pharm Pract 2010 Feb, 23(1):38-49.
23. Grommes J., Soehnlein O. Contribution of neutrophils to acute lung injury. Mol Med 2011 Mar-Apr, 17(3-4):293-307.
24. Soehnlein O., Oehmcke S., Ma X., Rothfuchs A.G., Frithiof R., van Rooijen N., et al. Neutrophil degranulation mediates severe lung damage triggered by streptococcal M1 protein. Eur Respir J 2008 Aug, 32(2):405-412.
25. Looney M.R., Su X., Van Ziffle J.A., Lowell C.A., Matthay M.A. Neutrophils and their Fc gamma receptors are essential in a mouse model of transfusion-related acute lung injury. J Clin Invest 2006 Jun, 116(6):1615-1623.
26. Grommes J., Vijayan S., Drechsler M., Hartwig H., Morgelin M., Dembinski R., et al. Simvastatin reduces endotoxin-induced acute lung injury by decreasing neutrophil recruitment and radical formation. PLoS One 2012, 7(6):e38917.
27. Fessler M.B., Young S.K., Jeyaseelan S., Lieber J.G., Arndt P.G., Nick J.A., et al. A role for hydroxy-methylglutaryl coenzyme a reductase in pulmonary inflammation and host defense. Am J Respir Crit Care Med 2005 Mar 15, 171(6):606-615.
28. Jacobson J.R., Barnard J.W., Grigoryev D.N., Ma S.F., Tuder R.M., Garcia J.G. Simvastatin attenuates vascular leak and inflammation in murine inflammatory lung injury. Am J Physiol Lung Cell Mol Physiol 2005 Jun, 288(6):L1026-L1032.
29. Kaneider N.C., Reinisch C.M., Dunzendorfer S., Meierhofer C., Djanani A., Wiedermann C.J. Induction of apoptosis and inhibition of migration of inflammatory and vascular wall cells by cerivastatin. Atherosclerosis 2001 Sep, 158(1):23-33.
30. Erkkila L., Jauhiainen M., Laitinen K., Haasio K., Tiirola T., Saikku P., et al. Effect of simvastatin, an established lipid-lowering drug, on pulmonary Chlamydia pneumoniae infection in mice. Antimicrob Agents Chemother 2005 Sep, 49(9):3959-3962.
31. Conran N., Saad S.T., Costa F.F., Ikuta T. Leukocyte numbers correlate with plasma levels of granulocyte-macrophage colony-stimulating factor in sickle cell disease. Ann Hematol 2007 Apr, 86(4):255-261.
32. Nielsen A.G., Nielsen R.B., Riis A.H., Johnsen S.P., Sorensen H.T., Thomsen R.W. The impact of statin use on pneumonia risk and outcome: a combined population-based case-control and cohort study. Crit Care 2012 Jul 12, 16(4):R122.
33. Myles P.R., Hubbard R.B., McKeever T.M., Pogson Z., Smith C.J., Gibson J.E. Risk of community-acquired pneumonia and the use of statins, ace inhibitors and gastric acid suppressants: a population-based case-control study. Pharmacoepidemiol Drug Saf 2009 Apr, 18(4):269-275.
34. Dublin S., Jackson M.L., Nelson J.C., Weiss N.S., Larson E.B., Jackson L.A. Statin use and risk of community acquired pneumonia in older people: population based case-control study. BMJ 2009 Jun 16, 338:b2137.
35. van de Garde E.M., Hak E., Souverein P.C., Hoes A.W., van den Bosch J.M., Leufkens H.G. Statin treatment and reduced risk of pneumonia in patients with diabetes. Thorax 2006 Nov, 61(11):957-961.
36. Vinogradova Y., Coupland C., Hippisley-Cox J. Risk of pneumonia in patients taking statins: population-based nested case-control study. Br J Gen Pract 2011 Nov, 61(592):e742-e748.
37. Schlienger R.G., Fedson D.S., Jick S.S., Jick H., Meier C.R. Statins and the risk of pneumonia: a population-based, nested case-control study. Pharmacotherapy 2007 Mar, 27(3):325-332.
38. Shrank W.H., Patrick A.R., Brookhart M.A. Healthy user and related biases in observational studies of preventive interventions: a primer for physicians. J Gen Intern Med 2011 May, 26(5):546-550.
39. Novack V., MacFadyen J., Malhotra A., Almog Y., Glynn R.J., Ridker P.M. The effect of rosuvastatin on incident pneumonia: results from the JUPITER trial. CMAJ 2012 Apr 17, 184(7):E367-E372.
40. Khan A.R., Riaz M., Bin Abdulhak A.A., Al-Tannir M.A., Garbati M.A., Erwin P.J., et al. The role of statins in prevention and treatment of community acquired pneumonia: a systematic review and meta-analysis. PLoS One 2013, 8(1):e52929.
41. Mortensen E.M., Pugh M.J., Copeland L.A., Restrepo M.I., Cornell J.E., Anzueto A., et al. Impact of statins and angiotensin-converting enzyme inhibitors on mortality of subjects hospitalised with pneumonia. Eur Respir J 2008 Mar, 31(3):611-617.
42. Yende S., Milbrandt E.B., Kellum J.A., Kong L., Delude R.L., Weissfeld L.A., et al. Understanding the potential role of statins in pneumonia and sepsis. Crit Care Med 2011 Aug, 39(8):1871-1878.
43. Rothberg M.B., Bigelow C., Pekow P.S., Lindenauer P.K. Association between statins given in hospital and mortality in pneumonia patients. J Gen Intern Med 2012 Mar, 27(3):280-286.
44. Majumdar S.R., McAlister F.A., Eurich D.T., Padwal R.S., Marrie T.J. Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort study. BMJ 2006 Nov 11, 333(7576):999.
45. Douglas I., Evans S., Smeeth L. Effect of statin treatment on short term mortality after pneumonia episode: cohort study. BMJ 2011 Apr 6, 342:d1642.
46. Mortensen E.M., Restrepo M.I., Anzueto A., Pugh J. The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia. Respir Res 2005 Jul 25, 6:82.
47. Chalmers J.D., Singanayagam A., Murray M.P., Hill A.T. Prior statin use is associated with improved outcomes in community-acquired pneumonia. Am J Med 2008 Nov, 121(11):1002 e1-1007 e1.
48. Thomsen R.W., Riis A., Kornum J.B., Christensen S., Johnsen S.P., Sorensen H.T. Preadmission use of statins and outcomes after hospitalization with pneumonia: population-based cohort study of 29,900 patients. Arch Intern Med 2008 Oct 27, 168(19):2081-2087.
49. Myles P.R., Hubbard R.B., Gibson J.E., Pogson Z., Smith C.J., McKeever T.M. The impact of statins, ACE inhibitors and gastric acid suppressants on pneumonia mortality in a UK general practice population cohort. Pharmacoepidemiol Drug Saf 2009 Aug, 18(8):697-703.
50. Mortensen E.M., Nakashima B., Cornell J., Copeland L.A., Pugh M.J., Anzueto A., et al. Population-based study of statins, angiotensin II receptor blockers, and angiotensin-converting enzyme inhibitors on pneumonia-related outcomes. Clin Infect Dis 2012 Dec, 55(11):1466-1473.
51. Yende S., van der Poll T., Lee M., Huang D.T., Newman A.B., Kong L., et al. The influence of pre-existing diabetes mellitus on the host immune response and outcome of pneumonia: analysis of two multicentre cohort studies. Thorax 2010 Oct, 65(10):870-877.
52. Chopra V., Rogers M.A., Buist M., Govindan S., Lindenauer P.K., Saint S., et al. Is statin use associated with reduced mortality after pneumonia? A systematic review and meta-analysis. Am J Med 2012 Nov, 125(11):1111-1123.
53. Patel J.M., Snaith C., Thickett D.R., Linhartova L., Melody T., Hawkey P., et al. Randomized double-blind placebo-controlled trial of 40mg/day of atorvastatin in reducing the severity of sepsis in ward patients (ASEPSIS Trial). Crit Care 2012 Dec 11, 16(6):R231.
54. Kruger P., Bailey M., Bellomo R., Cooper D.J., Harward M., Higgins A., et al. A multicenter randomized trial of atorvastatin therapy in intensive care patients with severe sepsis. Am J Respir Crit Care Med 2013 Apr, 187(7):743-750.
55. Kruger P.S., Harward M.L., Jones M.A., Joyce C.J., Kostner K.M., Roberts M.S., et al. Continuation of statin therapy in patients with presumed infection: a randomized controlled trial. Am J Respir Crit Care Med 2011 Mar 15, 183(6):774-781.
56. Novack V., Eisinger M., Frenkel A., Terblanche M., Adhikari N.K., Douvdevani A., et al. The effects of statin therapy on inflammatory cytokines in patients with bacterial infections: a randomized double-blind placebo controlled clinical trial. Intensive Care Med 2009 Jul, 35(7):1255-1260.
57. Ogu C.C., Maxa J.L. Drug interactions due to cytochrome P450. Proc (Bayl Univ Med Cent) 2000 Oct, 13(4):421-423.